AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Pharmacological Modulation of Brain Oscillations in Memory Processing

RecruitingEARLY Phase 1Ages 18 Years - 55 YearsAllUniversity of Texas Southwestern Medical Center
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed. The main questions it aims to answer are 1) whether scopolamine changes memory activity solely at encoding (the time when the person perceives and determines to remember an item or event) as has previously been found, or if it also can selectively impact retrieval (when the item or event which has been processed is recalled or remembered), and 2) what the nature of the brain activity changes is. Participants will complete two treatment arms. One of these will be with the drug, and the other will be with a saline solu

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Patient inclusion criteria: 1. Age 18 - 55 years, all races/ethnicities, and both genders are eligible. 2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care. 3. Able to read, understand, and provide written, dated informed consent prior to screening. 4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG. 5. Body mass index between 18-35 kg/m2. Patient exclusion criteria: 1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician. 2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. Note that pregnant patients are excluded from undergoing iEEG generally and all patients undergo a positive screening urine test for drugs of abuse at screening: cannabinoids, cocaine, amphetamines, barbiturates, opiates not otherwise explained by their prescribed medications. 3. History of renal insufficiency. 4. Unstable cardiac syndrome or active cardiac symptoms. 5. Patients with liver failure. 6. Patients with BPH. 7. Patients with autoimmune neuropathy. 8. Patients with uncontrolled hyperthyroidism. 9. Patients with a history of dementia. 10. Patient with a history of delirium after using transdermal scopolamine. 11. History of narrow-angle glaucoma. 12. History of pyloric obstruction or paralytic ileus. 13. History of myasthenia gravis, obstructive uropathy, porphyria, or myasthenia gravis.
๐Ÿ’Š

What it tests

  • Scopolamine (0.4mg)
  • Placebo
๐Ÿ“

Where

1 site
University of Texas Southwestern Medical Center
Dallas, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy